-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
38
1、CEO：
33，Medical Design&Outsourcing，Geoff Martha，，，。
Martha，20，，，，PC，。
，，，。
2020914，，，，，20209，BUOU。
20209，，，，。，。
，Martha，——，。
，，。
Martha，，，，，。
2、
Martha，。
34，Medical Design&Outsourcing，Greg Smith45，。
Martha，GregSmith、。
，Greg Smith，，，、。Greg Smith、，，。
，Greg SmithGoodyear（），52。
Prior to this, in December 2020, according to PR Newswire, Sean Salmon, Executive Vice President and President of Medtronic's Diabetes Operations, was appointed as Executive Vice President and President of Cardiovascular Products, effective January 1, 2021.
Salmon will continue to lead the diabetes operations department and will continue to serve as a member of the company's executive committee.
Salmon will continue to lead the diabetes operations department and will continue to serve as a member of the company's executive committee.
It is understood that Salmon succeeds Mike Coyle, who will leave Medtronic on December 31 to accept the position of CEO of a listed company.
In addition, according to the Medical Design & Outsourcing Web site information, excellent Medtronic corporate vice president and business transformation EllieHumphrey also left Medtronic, a senior vice president and chief restructuring officer of Zimmer Biomet.
Martha said that whenever a decision changes, there may always be some people leaving.
Providing executive talents to other companies in the industry means that they are also attracting suitable talents, but the challenge is how to retain talents.
I hope that Medtronic can become a talent factory and attract better talents at the same time.
Providing executive talents to other companies in the industry means that they are also attracting suitable talents, but the challenge is how to retain talents.
I hope that Medtronic can become a talent factory and attract better talents at the same time.
3.
The latest results are announced, the CEO remains optimistic
The latest results are announced, the CEO remains optimistic
On March 3, according to the information on the Medical Design&Outsourcing website, Martha said he was very pleased with Medtronic’s 2021 fiscal third quarter results.
On February 23, Medtronic announced the results for the third quarter of fiscal 2021.
According to the financial report, the net profit attributable to ordinary shareholders of the parent company in the third quarter of Medtronic was US$1.
270 billion, a year-on-year decrease of 33.
68%; operating income was US$7.
775 billion.
Increased by 0.
8% year-on-year.
According to the financial report, the net profit attributable to ordinary shareholders of the parent company in the third quarter of Medtronic was US$1.
270 billion, a year-on-year decrease of 33.
68%; operating income was US$7.
775 billion.
Increased by 0.
8% year-on-year.
According to information from the US Securities and Exchange Commission, in the third quarter, Medtronic’s revenue in the United States was US$3.
939 billion, accounting for 51% of the company’s revenue, a decrease of 2%; developed market revenue outside the US was US$2.
522 billion, accounting for 32% of the company’s revenue.
According to the report, it increased by 6%; emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue, with an organic growth of 1%.
939 billion, accounting for 51% of the company’s revenue, a decrease of 2%; developed market revenue outside the US was US$2.
522 billion, accounting for 32% of the company’s revenue.
According to the report, it increased by 6%; emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue, with an organic growth of 1%.
Prior to this, Medtronic announced the results of the second quarter of fiscal 2021.
During the reporting period, revenue was 7.
647 billion U.
S.
dollars, compared with 7.
706 billion U.
S.
dollars in the same period of the previous fiscal year, a year-on-year decrease of 0.
8%.
Net profit was 494 million U.
S.
dollars.
In the same period, 1.
371 billion US dollars, a year-on-year decrease of 64.
0%.
During the reporting period, revenue was 7.
647 billion U.
S.
dollars, compared with 7.
706 billion U.
S.
dollars in the same period of the previous fiscal year, a year-on-year decrease of 0.
8%.
Net profit was 494 million U.
S.
dollars.
In the same period, 1.
371 billion US dollars, a year-on-year decrease of 64.
0%.
Martha expressed his optimism about Medtronic’s future for five main reasons:
1.
The hospital market is relatively optimistic.
Medtronic’s fixed equipment is being sold in record quantities, US procedures will rebound, and Europe may lag by a few months.
The hospital market is relatively optimistic.
Medtronic’s fixed equipment is being sold in record quantities, US procedures will rebound, and Europe may lag by a few months.
2.
Strong product pipeline.
Medtronic reported that it received 46 FDA approvals in the third quarter and 220 since January 2020.
Among them, the sales of one pacemaker in the United States and the world have increased by 75% and 64%, respectively.
Strong product pipeline.
Medtronic reported that it received 46 FDA approvals in the third quarter and 220 since January 2020.
Among them, the sales of one pacemaker in the United States and the world have increased by 75% and 64%, respectively.
3.
The core is solid.
The surgical business has a strong quarterly performance, which has brought a lot of cash flow to the company and provided a longer time for solving the development of new technologies in areas such as TAVR.
The core is solid.
The surgical business has a strong quarterly performance, which has brought a lot of cash flow to the company and provided a longer time for solving the development of new technologies in areas such as TAVR.
4.
If the clinical trial of renal denervation technology is successful, it will be submitted to the FDA for approval in the fall.
If the clinical trial of renal denervation technology is successful, it will be submitted to the FDA for approval in the fall.
5.
The surgical robot business is expected to make progress.
The surgical robot business is expected to make progress.
Medical Network News on March 8
1.
Medtronic CEO : The latest adjustments are announced
Medtronic CEO : The latest adjustments are announced
On March 3, according to the information from Medical Design&Outsourcing, a professional medical equipment website, Medtronic CEO Geoff Martha stated that Medtronic is undergoing a reorganization, which will free the frontline forces from the early entanglement and give the company a more competitive edge in peer competition.
According to Martha, the reorganization plan created 20 semi-autonomous operating departments and divided the company into two tiers to help improve agility, but its operating model is broader than the structural model, just like from the mainframe to the PC.
The software must still be rewritten.
The software must still be rewritten.
In the next step, Medtronic will formulate operating standards and procedures, including product development, with the aim of simplifying the process so that various business units can seize market share from competitors.
On September 14, 2020, Cyberlane confirmed from authoritative channels that Medtronic will split its original business into 20 business units.
At the same time, in the next few months, Medtronic will simplify its operating model.
The monthly adjustment has started, and BU has been changed to OU.
At the same time, in the next few months, Medtronic will simplify its operating model.
The monthly adjustment has started, and BU has been changed to OU.
In addition, at the beginning of September 2020, Bloomberg News revealed that Medtronic CEO Bu will reorganize the company to increase revenue capabilities.
Medtronic has formulated a strategy for partial adjustment and overall reorganization based on its advantages.
The scope and focus of the two are different.
Two-way reform is the plan that Medtronic will implement in the future.
Medtronic has formulated a strategy for partial adjustment and overall reorganization based on its advantages.
The scope and focus of the two are different.
Two-way reform is the plan that Medtronic will implement in the future.
Recently, Martha also said that Medtronic’s management is developing a compensation plan that will provide bonuses as market share increases, but it still takes several quarters to learn how to measure market share more accurately.
At the same time, Medtronic is also reviewing its mission statement.
The overall intent of the statement will not change, but the new statement will reflect the development of the medical device industry in the past five years .
The overall intent of the statement will not change, but the new statement will reflect the development of the medical device industry in the past five years .
Martha pointed out that not all start-up competitors have enough funds to compete with Medtronic from all angles, because they have not really solved some of the problems of the nature of competition and the development of things.
In contrast, Medtronic’s new culture has A more competitive way of thinking.
In contrast, Medtronic’s new culture has A more competitive way of thinking.
2.
Announcement of Medtronic's high-level changes
Announcement of Medtronic's high-level changes
Martha said that the aforementioned changes of Medtronic will also create new opportunities for employees of Medtronic and other companies.
On March 4th, according to the information on the Medical Design&Outsourcing website, Greg Smith, Executive Vice President of Wal-Mart's U.
S.
Supply Chain, will join Medtronic on April 5th as Executive Vice President of Global Operations and Supply Chain.
S.
Supply Chain, will join Medtronic on April 5th as Executive Vice President of Global Operations and Supply Chain.
According to Martha, GregSmith is currently the person in charge of one of Wal-Mart's largest and most complex supply chains in the world.
It is understood that Greg Smith has formulated and implemented relevant strategies to change Wal-Mart's supply chain, so as to create a good working environment while promoting sales and reducing costs.
At the same time, Greg Smith also established Wal-Mart's sales, operations and quality organization plan to improve forecast accuracy and pursue zero loss.
At the same time, Greg Smith also established Wal-Mart's sales, operations and quality organization plan to improve forecast accuracy and pursue zero loss.
Prior to his position at Wal-Mart, Greg Smith also served as Senior Vice President of Global Operations at Goodyear (Goodyear Tire & Rubber Company), responsible for 52 production sites in four global business units.
Prior to this, in December 2020, according to PR Newswire, Sean Salmon, Executive Vice President and President of Medtronic's Diabetes Operations, was appointed as Executive Vice President and President of Cardiovascular Products, effective January 1, 2021.
Salmon will continue to lead the diabetes operations department and will continue to serve as a member of the company's executive committee.
Salmon will continue to lead the diabetes operations department and will continue to serve as a member of the company's executive committee.
It is understood that Salmon succeeds Mike Coyle, who will leave Medtronic on December 31 to accept the position of CEO of a listed company.
In addition, according to the Medical Design & Outsourcing Web site information, excellent Medtronic corporate vice president and business transformation EllieHumphrey also left Medtronic, a senior vice president and chief restructuring officer of Zimmer Biomet.
Martha said that whenever a decision changes, there may always be some people leaving.
Providing executive talents to other companies in the industry means that they are also attracting suitable talents, but the challenge is how to retain talents.
I hope that Medtronic can become a talent factory and attract better talents at the same time.
Providing executive talents to other companies in the industry means that they are also attracting suitable talents, but the challenge is how to retain talents.
I hope that Medtronic can become a talent factory and attract better talents at the same time.
3.
The latest results are announced, the CEO remains optimistic
The latest results are announced, the CEO remains optimistic
On March 3, according to the information on the Medical Design&Outsourcing website, Martha said he was very pleased with Medtronic’s 2021 fiscal third quarter results.
On February 23, Medtronic announced the results for the third quarter of fiscal 2021.
According to the financial report, the net profit attributable to ordinary shareholders of the parent company in the third quarter of Medtronic was US$1.
270 billion, a year-on-year decrease of 33.
68%; operating income was US$7.
775 billion.
Increased by 0.
8% year-on-year.
According to the financial report, the net profit attributable to ordinary shareholders of the parent company in the third quarter of Medtronic was US$1.
270 billion, a year-on-year decrease of 33.
68%; operating income was US$7.
775 billion.
Increased by 0.
8% year-on-year.
According to information from the US Securities and Exchange Commission, in the third quarter, Medtronic’s revenue in the United States was US$3.
939 billion, accounting for 51% of the company’s revenue, a decrease of 2%; developed market revenue outside the US was US$2.
522 billion, accounting for 32% of the company’s revenue.
According to the report, it increased by 6%; emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue, with an organic growth of 1%.
939 billion, accounting for 51% of the company’s revenue, a decrease of 2%; developed market revenue outside the US was US$2.
522 billion, accounting for 32% of the company’s revenue.
According to the report, it increased by 6%; emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue, with an organic growth of 1%.
Prior to this, Medtronic announced the results of the second quarter of fiscal 2021.
During the reporting period, revenue was 7.
647 billion U.
S.
dollars, compared with 7.
706 billion U.
S.
dollars in the same period of the previous fiscal year, a year-on-year decrease of 0.
8%.
Net profit was 494 million U.
S.
dollars.
In the same period, 1.
371 billion US dollars, a year-on-year decrease of 64.
0%.
During the reporting period, revenue was 7.
647 billion U.
S.
dollars, compared with 7.
706 billion U.
S.
dollars in the same period of the previous fiscal year, a year-on-year decrease of 0.
8%.
Net profit was 494 million U.
S.
dollars.
In the same period, 1.
371 billion US dollars, a year-on-year decrease of 64.
0%.
Martha expressed his optimism about Medtronic’s future for five main reasons:
1.
The hospital market is relatively optimistic.
Medtronic’s fixed equipment is being sold in record quantities, US procedures will rebound, and Europe may lag by a few months.
The hospital market is relatively optimistic.
Medtronic’s fixed equipment is being sold in record quantities, US procedures will rebound, and Europe may lag by a few months.
2.
Strong product pipeline.
Medtronic reported that it received 46 FDA approvals in the third quarter and 220 since January 2020.
Among them, the sales of one pacemaker in the United States and the world have increased by 75% and 64%, respectively.
Strong product pipeline.
Medtronic reported that it received 46 FDA approvals in the third quarter and 220 since January 2020.
Among them, the sales of one pacemaker in the United States and the world have increased by 75% and 64%, respectively.
3.
The core is solid.
The surgical business has a strong quarterly performance, which has brought a lot of cash flow to the company and provided a longer time for solving the development of new technologies in areas such as TAVR.
The core is solid.
The surgical business has a strong quarterly performance, which has brought a lot of cash flow to the company and provided a longer time for solving the development of new technologies in areas such as TAVR.
4.
If the clinical trial of renal denervation technology is successful, it will be submitted to the FDA for approval in the fall.
If the clinical trial of renal denervation technology is successful, it will be submitted to the FDA for approval in the fall.
5.
The surgical robot business is expected to make progress.
The surgical robot business is expected to make progress.
Medical Network News on March 8
1.
Medtronic CEO : The latest adjustments are announced
1. Medtronic CEO : The latest adjustments are announced
Medtronic CEO : The latest adjustments are announced
On March 3, according to the information from Medical Design&Outsourcing, a professional medical equipment website, Medtronic CEO Geoff Martha stated that Medtronic is undergoing a reorganization, which will free the frontline forces from the early entanglement and give the company a more competitive edge in peer competition.
According to Martha, the reorganization plan created 20 semi-autonomous operating departments and divided the company into two tiers to help improve agility, but its operating model is broader than the structural model, just like from the mainframe to the PC.
The software must still be rewritten.
The software must still be rewritten.
In the next step, Medtronic will formulate operating standards and procedures, including product development, with the aim of simplifying the process so that various business units can seize market share from competitors.
Standard Standard Standard On September 14, 2020, Cyberlane confirmed from authoritative channels that Medtronic will split its original business into 20 business units.
At the same time, in the next few months, Medtronic will simplify its operating model.
The monthly adjustment has started, and BU has been changed to OU.
At the same time, in the next few months, Medtronic will simplify its operating model.
The monthly adjustment has started, and BU has been changed to OU.
In addition, at the beginning of September 2020, Bloomberg News revealed that Medtronic CEO Bu will reorganize the company to increase revenue capabilities.
Medtronic has formulated a strategy for partial adjustment and overall reorganization based on its advantages.
The scope and focus of the two are different.
Two-way reform is the plan that Medtronic will implement in the future.
Medtronic has formulated a strategy for partial adjustment and overall reorganization based on its advantages.
The scope and focus of the two are different.
Two-way reform is the plan that Medtronic will implement in the future.
Recently, Martha also said that Medtronic’s management is developing a compensation plan that will provide bonuses as market share increases, but it still takes several quarters to learn how to measure market share more accurately.
At the same time, Medtronic is also reviewing its mission statement.
The overall intent of the statement will not change, but the new statement will reflect the development of the medical device industry in the past five years .
Medical equipment medical equipment medical equipmentThe overall intent of the statement will not change, but the new statement will reflect the development of the medical device industry in the past five years .
Martha pointed out that not all start-up competitors have enough funds to compete with Medtronic from all angles, because they have not really solved some of the problems of the nature of competition and the development of things.
In contrast, Medtronic’s new culture has A more competitive way of thinking.
In contrast, Medtronic’s new culture has A more competitive way of thinking.
2.
Announcement of Medtronic's high-level changes
2. Announcement of Medtronic's high-level changes
Announcement of Medtronic's high-level changes
Martha said that the aforementioned changes of Medtronic will also create new opportunities for employees of Medtronic and other companies.
On March 4th, according to the information on the Medical Design&Outsourcing website, Greg Smith, Executive Vice President of Wal-Mart's U.
S.
Supply Chain, will join Medtronic on April 5th as Executive Vice President of Global Operations and Supply Chain.
S.
Supply Chain, will join Medtronic on April 5th as Executive Vice President of Global Operations and Supply Chain.
According to Martha, GregSmith is currently the person in charge of one of Wal-Mart's largest and most complex supply chains in the world.
It is understood that Greg Smith has formulated and implemented relevant strategies to change Wal-Mart's supply chain, so as to create a good working environment while promoting sales and reducing costs.
At the same time, Greg Smith also established Wal-Mart's sales, operations and quality organization plan to improve forecast accuracy and pursue zero loss.
At the same time, Greg Smith also established Wal-Mart's sales, operations and quality organization plan to improve forecast accuracy and pursue zero loss.
Prior to his position at Wal-Mart, Greg Smith also served as Senior Vice President of Global Operations at Goodyear (Goodyear Tire & Rubber Company), responsible for 52 production sites in four global business units.
Prior to this, in December 2020, according to PR Newswire, Sean Salmon, Executive Vice President and President of Medtronic's Diabetes Operations, was appointed as Executive Vice President and President of Cardiovascular Products, effective January 1, 2021.
Salmon will continue to lead the diabetes operations department and will continue to serve as a member of the company's executive committee.
Salmon will continue to lead the diabetes operations department and will continue to serve as a member of the company's executive committee.
It is understood that Salmon succeeds Mike Coyle, who will leave Medtronic on December 31 to accept the position of CEO of a listed company.
In addition, according to the Medical Design & Outsourcing Web site information, excellent Medtronic corporate vice president and business transformation EllieHumphrey also left Medtronic, a senior vice president and chief restructuring officer of Zimmer Biomet.
Enterprise business enterprise Martha said that whenever a decision changes, there may always be some people leaving.
Providing executive talents to other companies in the industry means that they are also attracting suitable talents, but the challenge is how to retain talents.
I hope that Medtronic can become a talent factory and attract better talents at the same time.
Talent Talent TalentProviding executive talents to other companies in the industry means that they are also attracting suitable talents, but the challenge is how to retain talents.
I hope that Medtronic can become a talent factory and attract better talents at the same time.
3.
The latest results are announced, the CEO remains optimistic
The latest results are announced, the CEO remains optimistic
On March 3, according to the information on the Medical Design&Outsourcing website, Martha said he was very pleased with Medtronic’s 2021 fiscal third quarter results.
On February 23, Medtronic announced the results for the third quarter of fiscal 2021.
According to the financial report, the net profit attributable to ordinary shareholders of the parent company in the third quarter of Medtronic was US$1.
270 billion, a year-on-year decrease of 33.
68%; operating income was US$7.
775 billion.
Increased by 0.
8% year-on-year.
According to the financial report, the net profit attributable to ordinary shareholders of the parent company in the third quarter of Medtronic was US$1.
270 billion, a year-on-year decrease of 33.
68%; operating income was US$7.
775 billion.
Increased by 0.
8% year-on-year.
According to information from the US Securities and Exchange Commission, in the third quarter, Medtronic’s revenue in the United States was US$3.
939 billion, accounting for 51% of the company’s revenue, a decrease of 2%; developed market revenue outside the US was US$2.
522 billion, accounting for 32% of the company’s revenue.
According to the report, it increased by 6%; emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue, with an organic growth of 1%.
939 billion, accounting for 51% of the company’s revenue, a decrease of 2%; developed market revenue outside the US was US$2.
522 billion, accounting for 32% of the company’s revenue.
According to the report, it increased by 6%; emerging market revenue was US$1.
314 billion, accounting for 17% of the company’s revenue, with an organic growth of 1%.
Prior to this, Medtronic announced the results of the second quarter of fiscal 2021.
During the reporting period, revenue was 7.
647 billion U.
S.
dollars, compared with 7.
706 billion U.
S.
dollars in the same period of the previous fiscal year, a year-on-year decrease of 0.
8%.
Net profit was 494 million U.
S.
dollars.
In the same period, 1.
371 billion US dollars, a year-on-year decrease of 64.
0%.
During the reporting period, revenue was 7.
647 billion U.
S.
dollars, compared with 7.
706 billion U.
S.
dollars in the same period of the previous fiscal year, a year-on-year decrease of 0.
8%.
Net profit was 494 million U.
S.
dollars.
In the same period, 1.
371 billion US dollars, a year-on-year decrease of 64.
0%.
Martha expressed his optimism about Medtronic’s future for five main reasons:
1.
The hospital market is relatively optimistic.
Medtronic’s fixed equipment is being sold in record quantities, US procedures will rebound, and Europe may lag by a few months.
Hospital hospital hospitalThe hospital market is relatively optimistic.
Medtronic’s fixed equipment is being sold in record quantities, US procedures will rebound, and Europe may lag by a few months.
2.
Strong product pipeline.
Medtronic reported that it received 46 FDA approvals in the third quarter and 220 since January 2020.
Among them, the sales of one pacemaker in the United States and the world have increased by 75% and 64%, respectively.
Strong product pipeline.
Medtronic reported that it received 46 FDA approvals in the third quarter and 220 since January 2020.
Among them, the sales of one pacemaker in the United States and the world have increased by 75% and 64%, respectively.
3.
The core is solid.
The surgical business has a strong quarterly performance, which has brought a lot of cash flow to the company and provided a longer time for solving the development of new technologies in areas such as TAVR.
The core is solid.
The surgical business has a strong quarterly performance, which has brought a lot of cash flow to the company and provided a longer time for solving the development of new technologies in areas such as TAVR.
4.
If the clinical trial of renal denervation technology is successful, it will be submitted to the FDA for approval in the fall.
If the clinical trial of renal denervation technology is successful, it will be submitted to the FDA for approval in the fall.
5.
The surgical robot business is expected to make progress.
The surgical robot business is expected to make progress.
